Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

In this segment, Dr. Vachhani and Dr. Rampal discuss interferon therapy for polycythemia vera (PV), from early daily interferons to pegylated interferon alfa-2a (Pegasys) and the newer ropeginterferon ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the ...

Illinois Municipal Retirement Fund lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Takeda scores with polycythemia vera drug in phase 3 trial. A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...